Towards a new Value-based scenario for the management of dementia in Italy: a SINdem delphi consensus study
- PMID: 40237973
- PMCID: PMC12152079
- DOI: 10.1007/s10072-025-08143-5
Towards a new Value-based scenario for the management of dementia in Italy: a SINdem delphi consensus study
Abstract
This national expert-based Delphi-consensus aims at formulating recommendations on the management of dementia care in Italy. This effort seems important and timely given in light of a new scenario arising from a new biological definition of Alzheimer's disease (AD) and the availability of disease-modifying treatments (DMTs).
Methods: the Steering Committee of the Italian Neurological Society for dementia (SINdem) created appropriate statements. Invited SINdem experts were requested to vote on the statements according to a modified three-round Delphi method. Only those statements reaching Grade A (full agreement ≥ 75%) or B (overall agreement ≥ 80% and full disagreement < 5%) were included in the final document. Round answers' consistency was graded using the Cohen's k and within-class correlation coefficient.
Results: Forty-six experts voted on 20 statements, which focused on the following aspects: i) organization of care services from early diagnosis to the management of advanced clinical stages; ii) access to biomarkers for a biological diagnosis of AD; iii) requirements necessary for the administration of DMTs; iv) main actors and pathways for the management of patients suffering from cognitive disorders. At the end of the process, 4 statements (20%) received a Grade A consensus, while 16 (80%) reached a Grade B consensus. Although the responses reflect heterogeneity among Italian regions, there was a fair degree of consistency for all statements.
Conclusion: The high strength of this expert-based Delphi-consensus may offer guidance for improving the patient's journey of individuals with cognitive decline from a biological diagnosis to DMTs administration and may possibly offer hints to the Health Systems on dementia.
Keywords: Alzheimer care management; Biological diagnosis; Delphi consensus; Dementia; Disease modifying drugs; Italy.
© 2025. The Author(s).
Conflict of interest statement
Declarations: On behalf of all authors, the corresponding author states that there is no conflict of interest. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. The research does not involve data or materials from human participants and ethic approval or consent were not needed as confirmed by the Hospital Ethic Committee of Gemelli Hospital. Competing interests: The authors have no relevant financial or non-financial interests to disclose.
References
-
- Dementia, https://www.who.int/news-room/fact-sheets/detail/dementia accessed 8 Jan 2024
-
- Wimo A, Seeher K, Cataldi R, et al. The worldwide costs of dementia in 2019. Alzheimers Dement 2023; 19: 2865–2873. Global action plan on the public health response to dementia 2017–2025, https://www.who.int/publications-detail-redirect/9789241513487 accessed 8 Jan 2024 - PMC - PubMed
-
- Georges J, Bintener C, Miller O. Dementia in Europe Yearbook 2019: Estimating the prevalence of dementia in Europe. Alzheimer Europe
-
- Monteiro AR, Barbosa DJ, Remião F et al (2023) Alzheimer’s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem Pharmacol 211:115522 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical